Imatinib improves the intratumoral bioavailability of chemotherapeutic approaches diminishing interstitial pressure suggesting its use in combination with chemotherapy.27,28 Clinical tumor response to the c-KIT/PDGFR/ABL tyrosine kinase inhibitor (TKI) imatinib has been occasionally reported in LGG.15,29,30 Nilotinib is a second-generation TKI developed as a selective and potent inhibitor of the TK activity of BCR-ABL. Here, PDGFRB is linked to neoplasm.